- Chrissie Cole | July 28, 2009 10:11 PM | Eastern Massachusetts, MA
Category:
FDA & Prescription Drugs
A trial of sildenafil intended to determine if the drug could be used to treat pulmonary hypertension in some patients with sickle cell disease has been halted a year early by the National...
- Chrissie Cole | March 27, 2008 1:52 AM | Eastern Massachusetts, MA
Category:
FDA & Prescription Drugs
The U.S. Food and Drug Administration (FDA), is investigating a possible link between the use of Singulair and suicidal behavior, mood changes and suicide.Singulair, a leukotrient receptor antagonist, is used to treat asthma and the symptoms of rhinitis (irritation and inflammation of the nose), while preventing exercise-induced asthma episodes.Patients are advised not to stop taking Singluair...
- Bruce Bierhans | December 19, 2007 12:59 PM | Cape Cod, MA
Category:
Automobile Accidents
The Massachusetts Supreme Judicial Court recently issued a very practical but controversial decision. The court held that the mother of a boy struck and killed by a car could sue the drivers doctor because the doctor failed to warn the driver of the risks associated with taking certain medications.This may appear harsh, but it is nothing more than a logical extension of the existing law of...
- Chrissie Cole | December 10, 2007 5:39 PM | Cape Cod, MA
Category:
FDA & Prescription Drugs
The FDA warns patients and physicians that desmopressin, a drug used to control bed-wetting in children, can increase the risk of seizures and death.The FDA has received 61 reports of seizures - including two fatalities - amongst patients taking desmopressin. Desmopressin is used to lower the amount of water eliminated in urine. In some cases the drug lowered the amount of sodium in the...
- Chrissie Cole | November 05, 2007 1:35 AM | Eastern Massachusetts, MA
Category:
FDA & Prescription Drugs
The Food and Drug Administration (FDA) has requested Bayer Pharmaceuticals Corp., halt all marketing of Trasylol, a drug used to stop bleeding during heart surgery. The decision was made to pull the drug off the market following a Canadian study that showed an increased risk of death during use.On Oct. 26, FDA issued an Early Communication about an Ongoing Safety Review of Trasylol in response...